Jithma Abeykoon: NGS Profiling Is Essential for All Rosai-Dorfman Disease Tumors

Jithma Abeykoon, Medical Doctor at Mayo Clinic, shared on X: 'NGS needs to be done on all RDD tumors. Important clinically and theraputically. Title: Mutational profiling links biologically relevant variants to multisystemic Rosai-Dorfman disease Authors: Gordon J. Ruan, Steven Tessier, Aishwarya Ravindran, Ubenthira Patgunarajah, David Pottinger, Saurabh Zanwar, Aldo A. Acosta-Medina, Karen L. Rech, Jason R. Young, Jay H. Ryu, Matthew J. Koster, W. Oliver Tobin, Mithun V. Shah, N. Nora Bennani, Robert Vassallo, Muhamad Alhaj Moustafa, Talal Hilal, Jennifer Jiang, Corrie Bach, Lucinda M. Gruber, Alana E. Gill, Ginny-Tyler Meadows, Adita Saha, Diana Morlote, Gaurav Goyal, Ronald S. Go, Jithma P. Abeykoon. See Our Publication. Mutational profiling links biologically relevant variants to multisystemic Rosai-Dorfman disease.' You can also read: Preserving Lymph Nodes During Cancer Surgery Could Improve Immunotherapy Response- Lung Cancer Europe